Third Harmonic BioTHRD
About: Third Harmonic Bio Inc is a biopharmaceutical company focused on the development of the next wave of medicine for the treatment of inflammatory diseases, including dermal, respiratory, and gastrointestinal diseases. The company's product candidate, THB001, is a selective, oral small-molecule inhibitor of KIT, a cell surface receptor that serves as the master regulator of mast cell function and survival. Its other product candidate THB335, is a potent, selective, oral small molecule KIT inhibitor, for the treatment of multiple mast cell-driven inflammatory diseases of the skin, airway, and gastrointestinal tract.
Employees: 42
Fund manager confidence
Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)
88% more repeat investments, than reductions
Existing positions increased: 30 | Existing positions reduced: 16
46% more capital invested
Capital invested by funds: $359M [Q1] → $523M (+$164M) [Q2]
45% more first-time investments, than exits
New positions opened: 16 | Existing positions closed: 11
7% more funds holding
Funds holding: 71 [Q1] → 76 (+5) [Q2]
4.91% more ownership
Funds ownership: 93.34% [Q1] → 98.26% (+4.91%) [Q2]
0% more funds holding in top 10
Funds holding in top 10: 1 [Q1] → 1 (+0) [Q2]
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
1 analyst rating
Morgan Stanley Michael Ulz 43% 1-year accuracy 6 / 14 met price target | 52%upside $20 | Overweight Upgraded | 9 Aug 2024 |
